Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Elite Pharmaceuticals Inc. (ELTP) had Revenue of $84.04M for the most recently reported fiscal year, ending 2025-03-31.

Quarterly Annual

Figures for fiscal year ending 2025-03-31

Income Statement Financials
Revenue	$84.04M
Net Income	$-4.31M
Cost of Goods Sold	$43.96M
Gross Profit	$40.09M
Operating Expenses	$64.44M
Operating Income	$19.60M
Non-Operating Income/Expense	$-19.65M
Pre-Tax Income	$-0.05M
Normalized Pre-Tax Income	$-0.05M
Income after Taxes	$-4.31M
Income from Continuous Operations	$-4.31M
Consolidated Net Income/Loss	$-4.31M
Normalized Income after Taxes	$-4.31M
EBIT	$19.60M
EBITDA	$21.74M
Weighted-Average Shares Outstanding (Basic)	1.07B
Weighted-Average Shares Outstanding (Diluted)	1.07B
Earnings per Share (EPS) (Basic)	$0.00
Earnings per Share (EPS) (Diluted)	$0.00
Balance Sheet Financials
Current Assets	$57.74M
Property, Plant, and Equipment	$10.33M
Long-Term Assets	$38.65M
Total Assets	$96.39M
Current Liabilities	$11.84M
Long-Term Debt	$4.28M
Long-Term Liabilities	$31.03M
Total Liabilities	$42.87M
Common Equity	$53.52M
Tangible Shareholders Equity	$47.88M
Shareholders Equity	$53.52M
Common Shares Outstanding	1.07B
Cash Flow Statement Financials
Cash Flow from Operating Activities	$7.46M
Cash Flow from Investing Activities	$-2.40M
Cash Flow from Financial Activities	$-0.83M
Beginning Cash	$7.54M
End Cash	$11.77M
Increase/Decrease in Cash	$4.23M
Stock-Based Compensation	$0.23M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.88
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.07
Debt to Equity Ratio	0.17
Gross Margin	47.70%
Operating Margin	23.32%
EBIT Margin	23.32%
EBITDA Margin	25.86%
Pre-Tax Profit Margin	-0.06%
Profit Margin	-5.13%
Free Cash Flow	$5.96M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.87
Inventory Turnover	2.71
Receiveable Turnover	2.88
Days Sales in Receivables	126.85
Return on Equity	-8.06%
Return on Tangible Equity	-9.01%
Return on Assets	-4.48%
Return on Investments	-7.47%
Book Value Per Share	$0.05
Free Cash Flow per Share	$0.01
Operating Cash Flow per Share	$0.01

Data from Zacks Investment Research, Inc.